These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7697926)

  • 1. Autoproliferation in HIV-1-infected patients undergoing active HIV-1-specific immunotherapy.
    Trauger RJ; Giermakowska W; Wormsley S; Turner J; Jensen FC; Carlo DJ
    Clin Exp Immunol; 1995 Apr; 100(1):7-12. PubMed ID: 7697926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
    Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
    Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.
    Trauger RJ; Ferre F; Daigle AE; Jensen FC; Moss RB; Mueller SH; Richieri SP; Slade HB; Carlo DJ
    J Infect Dis; 1994 Jun; 169(6):1256-64. PubMed ID: 7910836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.
    Moss RB; Li L; Giermakowska WK; Lanza P; Turner JL; Wallace MR; Jensen FC; Richieri SP; Daigle AE; Theofan G; Carlo DJ
    J Hum Virol; 1998; 1(2):77-81. PubMed ID: 10195235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
    Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-Specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA.
    Moss RB; Diveley J; Jensen FC; Gouveia E; Savary J; Carlo DJ
    J Interferon Cytokine Res; 2000 Dec; 20(12):1131-7. PubMed ID: 11152580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).
    Moss RB; Wallace MR; Lanza P; Giermakowska W; Jensen FC; Theofan G; Chamberlin C; Richieri SP; Carlo DJ
    Clin Diagn Lab Immunol; 1998 May; 5(3):308-12. PubMed ID: 9605982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
    Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.
    Siliciano RF; Bollinger RC; Callahan KM; Hammond SA; Liu AY; Miskovsky EP; Rowell JF; Stanhope PE
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1349-52. PubMed ID: 1361352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination.
    Lanza P; Moss RB; Giermakowska W; Hancock RB; Richieri SP; Theofa G; Jensen FC; Salk PL; Carlo DJ
    Vaccine; 1998 Apr; 16(7):727-31. PubMed ID: 9562693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.
    Moss RB; Wallace MR; Steigbigel RT; Morrison SA; Giermakowska WK; Nardo CJ; Diveley JP; Carlo DJ
    Clin Exp Immunol; 2002 May; 128(2):359-64. PubMed ID: 11985528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides.
    Moss RB; Diveley J; Jensen F; Carlo DJ
    Vaccine; 2000 Jan; 18(11-12):1081-7. PubMed ID: 10590329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
    Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
    Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
    Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
    J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
    Trauger RJ; Daigle AE; Giermakowska W; Moss RB; Jensen F; Carlo DJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S74-82. PubMed ID: 7552517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of perforin on HIV-1-specific CD8+ lymphocytes after immunization with a gp120-depleted, whole-killed HIV-1 immunogen.
    Moss RB; Giermakowska WK; Wallace MR; Jensen FC; Maigetter RZ; Carlo DJ
    Clin Exp Immunol; 2001 May; 124(2):248-54. PubMed ID: 11422201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.
    Moss RB; Wallace MR; Giermakowska WK; Webb E; Savary J; Chamberlin-Brandt C; Theofan G; Musil R; Richieri SP; Jensen FC; Carlo DJ
    J Infect Dis; 1999 Sep; 180(3):641-8. PubMed ID: 10438350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.
    Turner JL; Kostman JR; Aquino A; Wright D; Szabo S; Bidwell R; Goodgame J; Daigle A; Kelley E; Jensen F; Duffy C; Carlo D; Moss RB
    HIV Med; 2001 Apr; 2(2):68-77. PubMed ID: 11737381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).
    Ferrari G; King K; Rathbun K; Place CA; Packard MV; Bartlett JA; Bolognesi DP; Weinhold KJ
    Clin Exp Immunol; 1995 Aug; 101(2):239-48. PubMed ID: 7544247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.